Agonistic Anti-CD137 Antibodies for T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents fail to effectively modulate immune responses to treat diseases involving immune suppression, such as cancer and infectious diseases, by not adequately promoting CD137 signaling.
Innovation Solution
Development of antibodies that specifically bind to CD137, enhancing its function and promoting immune activation, including increasing T cell activation and reducing Treg-mediated immune suppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used, then treatment of immune suppression diseases is attempted, but they fail to effectively modulate immune responses by not adequately promoting CD137 signaling
Solution Approach 1:
The patent develops agonistic anti-CD137 antibodies that specifically bind to CD137 and alter its signaling state from baseline to activated, thereby changing the functional parameter of immune response modulation. This direct targeting of CD137 signaling pathway overcomes the inadequacy of current agents that fail to sufficiently activate this pathway.
2Productivity
If agonistic anti-CD137 antibodies are administered, then T cell activation is enhanced and immune suppression is reduced, but the complexity of the therapeutic mechanism increases
Solution Approach 1:
The patent isolates and targets the specific CD137 signaling pathway component responsible for T cell activation and immune suppression regulation. By focusing on this single molecular target rather than attempting to modulate multiple immune pathways simultaneously, the therapy achieves high productivity in T cell activation while maintaining mechanistic simplicity through targeted single-antigen approach.
3Adaptability or versatility
If current therapeutic agents are used, then treatment coverage is provided, but they lack the specific ability to enhance CD137-mediated immune activation
Solution Approach 1:
The patent introduces agonistic anti-CD137 antibodies as intermediary molecules that bridge the gap between current therapeutic agents and the CD137 signaling pathway. These antibodies specifically bind to CD137 and induce conformational changes that enhance signaling, thereby mediating the transfer of immune activation potency that current agents lack.
Data Source
AI summary
The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.